Castle Biosciences Reports First Quarter 2025 Results
Provided By GlobeNewswire
Last update: May 5, 2025
Q1 2025 revenue increased 21% over Q1 2024 to $88 million
Q1 2025 total test reports for our core revenue drivers (DecisionDx®-Melanoma, DecisionDx®-SCC, TissueCypher®) increased 33% over Q1 2024
Read more at globenewswire.com
